[Skip to Navigation]
October 1987

Daily Psoralen Therapy in Vitiligo

Author Affiliations

Department of Dermatology Faculty of Medicine Al Arab Medical University Benghazi, Libya

Arch Dermatol. 1987;123(10):1279-1280. doi:10.1001/archderm.1987.01660340039016

To the Editor.—  Vitiligo constitutes nearly 2% of all skin disorders in Benghazi, Libya.1 It carries a dire social stigma, and patients are often desperate for treatment. All patients with vitiligo from the eastern parts of Libya are referred to our clinic for management.In the past, we prescribed trioxsalen, 0.6 to 0.8 mg/kg on alternate days, followed by sun exposure two to three hours later as recommended by Mosher et al.2 A recent analysis of data collected from our patients showed that nearly 60% of the patients failed to achieve a satisfactory degree of repigmentation, and some patients discontinued the therapy because of poor response. In the patients who did not respond to alternate-day therapy, it was then decided to administer trioxsalen in the same dosage daily, as recommended by Pasricha (personal communication).Initially, 20 patients were selected for daily therapy. Of these, 15 patients had lesions

Add or change institution